Benaroya Research Institute

First established in 1956 as the Virginia Mason Research Center in Seattle, Washington, the nonprofit institute developed a unique niche as a basic sciences research institute associated with a major medical center and a teaching program. Renamed in 2002 in recognition of the Benaroya family of Seattle, BRI now houses more than 275 scientific and administrative staff with a research volume of more than $71 million a year, including grants from the National Institutes of Health, JDRF, The Leona M. and Harry B. Helmsley Charitable Trust and the National Multiple Sclerosis Society. One in every 15 Americans suffers from an autoimmune disease—type 1 diabetes, multiple sclerosis (MS), Crohn’s disease and rheumatoid arthritis are just a few. And because many causes of autoimmune diseases are shared, people living with an autoimmune disease are more likely to suffer from more than one of these destructive diseases. Benaroya Research Institute at Virginia Mason (BRI) is one of the few research institutes in the world dedicated to discovering causes and cures to eliminate autoimmune and immune system diseases. At BRI, their scientists aren’t focused on eliminating one or two autoimmune diseases—they are taking on all 80. Because autoimmune diseases are connected, so is the way they're fighting them. They're  applying the breakthroughs they make against individual autoimmune diseases to make progress against them all. Through collaboration and cooperation between researchers, across clinical trials and with other institutions, they connect laboratory research to clinical trials and translate discoveries to real-life applications. As a world leader in scientific innovation, they're leveraging this progress to eliminate autoimmune and immune system diseases in the future. Their discoveries are also having significant impact on people living with autoimmune and immune system diseases today—by improving the ability to predict disease risk, facilitate treatment, decrease progression of these diseases and make related therapies safer and more effective. THEIR COLLABORATIONS WITH OTHER SCIENTISTS AND INSTITUTIONS SPAN THE GLOBE Immune Tolerance Network BRI leads the Immune Tolerance Network (ITN), a collaborative network for clinical research focused on the development of therapeutic approaches that lead to immune tolerance in asthma and allergy, autoimmune diseases such as type 1 diabetes, and solid organ transplantation. Learn more about the ITN or visit TrialNet BRI leads Type 1 Diabetes TrialNet, an international network that conducts clinical studies that evaluate new approaches to preventing, delaying and reversing the progression of type 1 diabetes. TrialNet is conducting clinical trials with researchers from 17 clinical centers in the United States and six internationally. An additional 200 affiliated research sites are participating in the TrialNet network.
See more


Staff at Benaroya Research Institute have experience in


  • health systems
  • research & development
  • development
  • monitoring / evaluation
  • infectious disease


  • dominican republic
  • brazil
  • india
  • oman


  • managerial experience
  • business development
  • experience in recruitment
  • international experience


Contract Awards

Research on Large Scale T Cell Immune Epitope Discovery (5)

United States Department of Health & Human Services (DHHS), National Institutes of Health (NIH) - United States

Provision of Services for Research On Large-Scale Discovery of T Cell Immune Epitopes

United States Department of Health & Human Services (DHHS), National Institutes of Health (NIH) - United States

Contact Benaroya Research Institute

{{contact.full_name}} - {{contact.headline || contact.employment_title}}
  • Updated {{contact.updated_at | date:'dd MMM yyyy'}}

Company Offices

  • United States (headquarters)
  • Seattle
  • 1201 Ninth Avenue